Dosing Equation for Tacrolimus Using Genetic Variants and Clinical Factors

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2011 Jun 16

PMID 21671989

Citations 65

Authors

Chaitali Passey

Angela K Birnbaum

Richard C Brundage

William S Oetting

Ajay K Israni

Pamala A Jacobson

Affiliations

Soon will be listed here.

Abstract

Aim: To develop a dosing equation for tacrolimus, using genetic and clinical factors from a large cohort of kidney transplant recipients. Clinical factors and six genetic variants were screened for importance towards tacrolimus clearance (CL/F).

Methods: Clinical data, tacrolimus troughs and corresponding doses were collected from 681 kidney transplant recipients in a multicentre observational study in the USA and Canada for the first 6 months post transplant. The patients were genotyped for 2,724 single nucleotide polymorphisms using a customized Affymetrix SNP chip. Clinical factors and the most important SNPs (rs776746, rs12114000, rs3734354, rs4926, rs3135506 and rs2608555) were analysed for their influence on tacrolimus CL/F.

Results: The CYP3A5*1 genotype, days post transplant, age, transplant at a steroid sparing centre and calcium channel blocker (CCB) use significantly influenced tacrolimus CL/F. The final model describing CL/F (l h(-1)) was: 38.4 ×[(0.86, if days 6-10) or (0.71, if days 11-180)]×[(1.69, if CYP3A5*1/*3 genotype) or (2.00, if CYP3A5*1/*1 genotype)]× (0.70, if receiving a transplant at a steroid sparing centre) × ([age in years/50](-0.4)) × (0.94, if CCB is present). The dose to achieve the desired trough is then prospectively determined using the individuals CL/F estimate.

Conclusions: The CYP3A5*1 genotype and four clinical factors were important for tacrolimus CL/F. An individualized dose is easily determined from the predicted CL/F. This study is important towards individualization of dosing in the clinical setting and may increase the number of patients achieving the target concentration. This equation requires validation in an independent cohort of kidney transplant recipients.

Citing Articles

Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome.

Dohl J, Treadwell Z, Norris C, Head E Alzheimers Dement. 2025; 21(3):e70034.

PMID: 40042516 PMC: 11881635. DOI: 10.1002/alz.70034.

Machine-learning model to predict the tacrolimus concentration and suggest optimal dose in liver transplantation recipients: a multicenter retrospective cohort study.

Yoon S, Lee J, Jung C, Suh K, Lee K, Yi N Sci Rep. 2024; 14(1):19996.

PMID: 39198694 PMC: 11358263. DOI: 10.1038/s41598-024-71032-y.

Tacrolimus-why pharmacokinetics matter in the clinic.

Henkel L, Jehn U, Tholking G, Reuter S Front Transplant. 2024; 2:1160752.

PMID: 38993881 PMC: 11235362. DOI: 10.3389/frtra.2023.1160752.

Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies.

Li Z, Wang X, Li D, Cheng S, Li Z, Guo H BMC Nephrol. 2024; 25(1):48.

PMID: 38321419 PMC: 10848431. DOI: 10.1186/s12882-024-03467-4.

Pharmacokinetic Evaluation of Tacrolimus in Chinese Adult Patients during the Early Stages Post-Lung Transplantation.

Cui Y, Pan Y, Zhu M, Jiao Z J Pers Med. 2023; 13(4).

PMID: 37109042 PMC: 10145266. DOI: 10.3390/jpm13040656.

References

Plant N, GIBSON G, Moore D . Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos. 2000; 28(5):493-6. View

MacPhee I, Fredericks S, Tai T, Syrris P, Carter N, Johnston A . The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004; 4(6):914-9. DOI: 10.1111/j.1600-6143.2004.00435.x. View

Jacobson P, Oetting W, Brearley A, Leduc R, Guan W, Schladt D . Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation. 2011; 91(3):300-8. PMC: 3579501. DOI: 10.1097/TP.0b013e318200e991. View

Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q . Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc. 2005; 37(1):178-81. DOI: 10.1016/j.transproceed.2005.01.077. View

Matas A . Minimization of steroids in kidney transplantation. Transpl Int. 2008; 22(1):38-48. PMC: 3553596. DOI: 10.1111/j.1432-2277.2008.00728.x. View

Hesselink D, van Schaik R, van der Heiden I, van der Werf M, Smak Gregoor P, Lindemans J . Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003; 74(3):245-54. DOI: 10.1016/S0009-9236(03)00168-1. View

Paterson D, Singh N . Interactions between tacrolimus and antimicrobial agents. Clin Infect Dis. 1998; 25(6):1430-40. DOI: 10.1086/516138. View

Li J, Wang X, Chen S, Liu L, Fu Q, Chen X . Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics J. 2010; 11(4):300-6. DOI: 10.1038/tpj.2010.42. View

Lam S, Partovi N, Ting L, Ensom M . Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?. Ann Pharmacother. 2008; 42(7):1037-47. DOI: 10.1345/aph.1k628. View

10.

OSeaghdha C, McQuillan R, Moran A, Lavin P, Dorman A, OKelly P . Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection. Clin Transplant. 2009; 23(4):462-8. DOI: 10.1111/j.1399-0012.2009.01021.x. View

11.

Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S . Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol. 2008; 103(6):546-52. DOI: 10.1111/j.1742-7843.2008.00327.x. View

12.

Hesselink D, van Schaik R, van Agteren M, de Fijter J, Hartmann A, Zeier M . CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics. 2008; 18(4):339-48. DOI: 10.1097/FPC.0b013e3282f75f88. View

13.

Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K . Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation. 2004; 78(8):1182-7. DOI: 10.1097/01.tp.0000137789.58694.b4. View

14.

Suzuki Y, Homma M, Doki K, Itagaki F, Kohda Y . Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects. Br J Clin Pharmacol. 2008; 66(1):154-5. PMC: 2485247. DOI: 10.1111/j.1365-2125.2008.03162.x. View

15.

Staatz C, Goodman L, Tett S . Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet. 2010; 49(3):141-75. DOI: 10.2165/11317350-000000000-00000. View

16.

Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V . Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009; 86(6):609-18. DOI: 10.1038/clpt.2009.210. View

17.

Hebert M, Lam A . Diltiazem increases tacrolimus concentrations. Ann Pharmacother. 1999; 33(6):680-2. DOI: 10.1345/aph.18356. View

18.

Li L, Weintraub L, Concepcion W, Martin J, Miller K, Salvatierra O . Potential influence of tacrolimus and steroid avoidance on early graft function in pediatric renal transplantation. Pediatr Transplant. 2008; 12(6):701-7. DOI: 10.1111/j.1399-3046.2007.00884.x. View

19.

Lamba J, Lin Y, Schuetz E, Thummel K . Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002; 54(10):1271-94. DOI: 10.1016/s0169-409x(02)00066-2. View

20.

Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K . Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc. 2005; 37(4):1730-2. DOI: 10.1016/j.transproceed.2005.02.073. View